Re: Not over
I agree with your sentiment. I think Pivekumab S. (IMGN632) is the ADC to watch, and it's entirely possible it will be a standard add-on to a second gen AML regimen; AML has a much larger total addressable market than Ovarian Cancer and any solid success would have driven our market cap north of $15B.
Furthermore, if we are just talking about Elahere, Enyedy has stated that the size of the EU market is BIGGER than that of the US market for which it had been assigned a $4B+ market cap by traders.
I sincerely think $10.1B is a bit low (never mind the $600mm in cash we have). Barring some major correction in either biotechs or the market in general due to world events, I'd also have preferred to see the cards for their earlier pipeline or at the very least conditional value rights afforded shareholders for this.
I don't doubt that existing results were taken into account during the negotiations with ABBV, but more transparency on their valuation process would have helped convince me. It doesn't help that Goldman who advised IMGN during this process assigned the company a neutral rating with a target of $16 per share.